Roche Holding AGXSWX:ROP +2.09%79 EV-to-FCF is 21.93 as of Jun. 25, 2026, which is 20% above its 10-year median of 18.25. GuruFocus rates XSWX:ROP with a GF Score™ of 79/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 562 Drug Manufacturers companies, Roche Holding AG ranks worse than 52.67% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Roche Holding AG's Enterprise Value is CHF286,728 Mil.
Roche Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13,073 Mil. Therefore, Roche Holding AG's EV-to-FCF for today is 21.93.
The historical rank and industry rank for Roche Holding AG's EV-to-FCF or its related term are showing as below:
XSWX:ROP'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.62 Med: 18.25 Max: 28.15
Current: 21.17
During the past 13 years, the highest EV-to-FCF of Roche Holding AG was 28.15. The lowest was 13.62. And the median was 18.25.
XSWX:ROP's EV-to-FCF is ranked worse than 52.67% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs XSWX:ROP: 21.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Roche Holding AG's PE Ratio (TTM) for today is calculated as:
Roche Holding AG's share price for today is CHF332.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF16.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Roche Holding AG EV-to-FCF Related Terms
Roche Holding AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Roche Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's EV-to-FCF falls into.
Roche Holding AG's current Enterprise Value is CHF286,728 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13,073 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:ROP) has a EV-to-FCF of 21.93 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Roche Holding AG and its competitors. This is 20% above median its historical median of 18.25. Over the past decade, Roche Holding AG's EV-to-FCF has ranged from 13.62 to 28.15. According to the industry distribution chart, Roche Holding AG ranks #296 out of 562 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is Roche Holding AG's EV-to-FCF too high?
Roche Holding AG's current EV-to-FCF of 21.93 is 20% above median its 10-year median of 18.25. Over the past 10 years, this metric has ranged from a low of 13.62 to a high of 28.15. The Drug Manufacturers industry median EV-to-FCF is 20.16. Roche Holding AG's value of 21.93 is 8.8% above this industry median. Based on the distribution chart, Roche Holding AG ranks #296 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #296 out of 562 companies for EV-to-FCF. This places Roche Holding AG in the lower half of its industry. The industry median EV-to-FCF is 20.16. Roche Holding AG's value of 21.93 is 8.8% above this benchmark. Historically, Roche Holding AG's own EV-to-FCF has ranged from 13.62 to 28.15 over the past decade. While the company's 10-year median is 18.25 vs. the industry median of 20.16, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current EV-to-FCF of 21.93 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current EV-to-FCF is 21.93, which is 20% above median its own 10-year median of 18.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current EV-to-FCF is 21.93, which is 20% above median its 10-year median of 18.25 and 8.8% above the Drug Manufacturers industry median of 20.16. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current EV-to-FCF is 21.93 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
EV-to-FCF: 21.93 (20% above median its 10-year median of 18.25)
GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
Industry Position: 8.8% above the Drug Manufacturers median (#296 of 562)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score
Get the complete analysis for XSWX:ROP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 
